Table 3.
Biochemically adrenal- cortisol insufficient n=108 | Biochemically adrenal- cortisol sufficient n=394 | p value | ||
---|---|---|---|---|
Anti-infectious | 62.0 (67) | 46.8 (184) | 0.005 | |
Pulmonary | 29.6 (32) | 18.5 (73) | 0.01 | |
Cardiovascular | 53.7 (58) | 60.7 (239) | 0.19 | |
Diuretics | 12.0 (13) | 18 (71) | 0.14 | |
Neuro- modulators | 66.7 (72) | 58.4 (230) | 0.12 | |
Hematologic | 48.1 (52) | 44.4 (175) | 0.49 | |
Endocrine | 40.7 (44) | 43.7 (172) | 0.59 | |
Chemotherapy & radiation | 13.0 (14) | 12.9 (51) | >0.99 | |
Gastrointestinal | 65.7 (71) | 65.2 (257) | 0.92 | |
Skeletal | 7.4 (8) | 10.9 (43) | 0.37 | |
Megestrol | 15.7 (17) | 8.4 (33) | 0.02 | |
Azole antifungals † | 11.1 (12) | 6.3 (25) | 0.10 | |
Mitotane/metyrapone | 0 | 0.3 (1) | ||
Etomidate | 0.9 (1) | 0 | ||
Prior glucocorticoids ‡ | 7.4 (8) | 9.1 (36) | 0.70 | |
Prior fludrocortisone | 2.8 (3) | 1.8 (7) | 0.45 |
presented as % (n)
Anti-fungal azole drugs including ketoconazole, fludroconazole and voriconazole
Patients who received glucocorticoids at doses equivalent to ≥ 30 mg daily hydrocortisone for ≥ 2 weeks up to 24 hours prior to cortrosyn injection.